S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
NASDAQ:PYXS

Pyxis Oncology (PYXS) Stock Price, News & Analysis

$4.16
-0.37 (-8.17%)
(As of 04/19/2024 ET)
Today's Range
$4.06
$4.53
50-Day Range
$3.65
$6.59
52-Week Range
$1.35
$6.85
Volume
668,072 shs
Average Volume
717,649 shs
Market Capitalization
$241.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

Pyxis Oncology MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
104.3% Upside
$8.50 Price Target
Short Interest
Bearish
6.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.85) to ($1.30) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.15 out of 5 stars

Medical Sector

761st out of 909 stocks

Biotechnology Industry

16th out of 26 stocks

PYXS stock logo

About Pyxis Oncology Stock (NASDAQ:PYXS)

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

PYXS Stock Price History

PYXS Stock News Headlines

PYXS Oct 2024 10.000 call
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
3 Biotech Stocks to Buy on the Dip: March 2024
Pyxis Oncology: Q4 Earnings Insights
Pyxis Oncology (PYXS) Receives a Buy from Leerink Partners
PYXS Apr 2024 10.000 call
PYXS Apr 2024 7.500 put
PYXS Jul 2024 7.500 call
See More Headlines
Receive PYXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pyxis Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
4/20/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PYXS
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.50
High Stock Price Target
$12.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+104.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-73,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.81 per share

Miscellaneous

Free Float
53,250,000
Market Cap
$241.82 million
Optionable
Optionable
Beta
1.51
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. John L. Flavin M.B.A. (Age 53)
    MBA, Ph.D., Co-Founder & Independent Chairman
    Comp: $87.5k
  • Dr. Lara S. Sullivan M.D.
    MBA, CEO, President & Director
  • Ms. Pamela Yanchik Connealy M.B.A. (Age 62)
    CFO & COO
    Comp: $709.7k
  • Mr. Ken Kobayashi FACP (Age 63)
    M.D., Chief Medical Officer
    Comp: $314.08k
  • Mr. Jitendra Wadhane (Age 43)
    Chief Accounting Officer, Senior VP of Finance & Corporate Controller
  • Dr. Balu N. Balasubramanian Ph.D.
    Interim Chief Technology Officer
  • Dr. Jan Pinkas Ph.D.
    Chief Scientific Officer
  • Dr. Charles T. Gombar Ph.D.
    Senior Vice President of Portfolio & Program Management

PYXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Pyxis Oncology stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pyxis Oncology in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PYXS shares.
View PYXS analyst ratings
or view top-rated stocks.

What is Pyxis Oncology's stock price target for 2024?

7 Wall Street research analysts have issued 12 month price targets for Pyxis Oncology's shares. Their PYXS share price targets range from $7.00 to $12.00. On average, they expect the company's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 104.3% from the stock's current price.
View analysts price targets for PYXS
or view top-rated stocks among Wall Street analysts.

How have PYXS shares performed in 2024?

Pyxis Oncology's stock was trading at $1.80 at the start of the year. Since then, PYXS shares have increased by 131.1% and is now trading at $4.16.
View the best growth stocks for 2024 here
.

Are investors shorting Pyxis Oncology?

Pyxis Oncology saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,700,000 shares, an increase of 65.6% from the March 15th total of 1,630,000 shares. Based on an average daily volume of 875,100 shares, the short-interest ratio is currently 3.1 days. Currently, 6.9% of the shares of the company are short sold.
View Pyxis Oncology's Short Interest
.

When is Pyxis Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our PYXS earnings forecast
.

How were Pyxis Oncology's earnings last quarter?

Pyxis Oncology, Inc. (NASDAQ:PYXS) posted its quarterly earnings data on Thursday, March, 21st. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.16.

When did Pyxis Oncology IPO?

Pyxis Oncology (PYXS) raised $158 million in an initial public offering (IPO) on Friday, October 8th 2021. The company issued 10,500,000 shares at $14.00-$16.00 per share.

How do I buy shares of Pyxis Oncology?

Shares of PYXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PYXS) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners